Back to Journals » International Journal of General Medicine » Volume 7

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations

Authors Alsaikhan B, Alrabeeah K, Carrier S

Received 23 December 2013

Accepted for publication 24 February 2014

Published 12 June 2014 Volume 2014:7 Pages 271—276


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Bader Alsaikhan, Khalid Alrabeeah, Serge Carrier

McGill University Health Centre, Montreal, Quebec, QC, Canada

Abstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.

Keywords: lower urinary tract symptoms, phosphodiesterase-5 inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]